Solution reagent kit QuantideX®

diagnosticfor qPCRfor BCR-ABL

Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts. QuantideX® qPCR BCR-ABL IS Kit BCR-ABL blood cancer cells Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts. Features & Benefits Analytical Characteristics Additional Resources Ordering Features & Benefits The QuantideX qPCR BCR-ABL IS Kit’s unprecedented level of sensitivity coupled to a simple-to-run, singlicate test, allows labs to reliably and reproducibly monitor much deeper molecular response. Reduced Complexity Ease-of-data analysis and reporting: Direct reporting on the International Scale (IS): No sample exchange or conversion factor calculations required QuantideX qPCR Reporter eliminates manual intervention to provide automated calculations and streamlined reporting Optimized Workflow Valuable operator hands-on time has been significantly reduced through: